tradingkey.logo

J&J Says Phase 3 Iconic-Advance 1&2 Studies Met Their Co-Primary Endpoints

ReutersMar 8, 2025 2:07 PM

- Johnson & Johnson JNJ.N:

  • J&J - ICOTROKINRA RESULTS SHOW POTENTIAL TO SET A NEW STANDARD OF TREATMENT IN PLAQUE PSORIASIS

  • J&J - PHASE 3 ICONIC-ADVANCE 1&2(E )STUDIES MET THEIR CO-PRIMARY ENDPOINTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI